Dr Nadolsky responds to wellness influencer Gary Brecka's comments about GLP-1 medications in a short reaction clip.
Recap by typeshit. Post by @drnadolsky on Instagram.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
A search result from Polskie Radio on oral semaglutide and weight loss, with no details given beyond the question itself.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
The interim access policy went to OMB review, and Hims & Hers shares rose nearly 6%. Leerink sizes the possible market at $2.2B a year.
A Facebook newsletter looks at how GLP-1 research is moving past diabetes and obesity into cardiovascular and kidney care.
Loading…